124 related articles for article (PubMed ID: 36576661)
21. The circRNA circPTPRA suppresses epithelial-mesenchymal transitioning and metastasis of NSCLC cells by sponging miR-96-5p.
Wei S; Zheng Y; Jiang Y; Li X; Geng J; Shen Y; Li Q; Wang X; Zhao C; Chen Y; Qian Z; Zhou J; Li W
EBioMedicine; 2019 Jun; 44():182-193. PubMed ID: 31160270
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of Wnt/β-catenin pathway reverses multi-drug resistance and EMT in Oct4
Liu L; Zhu H; Liao Y; Wu W; Liu L; Liu L; Wu Y; Sun F; Lin HW
Biomed Pharmacother; 2020 Jul; 127():110225. PubMed ID: 32428834
[TBL] [Abstract][Full Text] [Related]
23. Hypoxia induces resistance to ALK inhibitors in the H3122 non-small cell lung cancer cell line with an ALK rearrangement via epithelial-mesenchymal transition.
Kogita A; Togashi Y; Hayashi H; Sogabe S; Terashima M; De Velasco MA; Sakai K; Fujita Y; Tomida S; Takeyama Y; Okuno K; Nakagawa K; Nishio K
Int J Oncol; 2014 Oct; 45(4):1430-6. PubMed ID: 25096400
[TBL] [Abstract][Full Text] [Related]
24. Activation of histamine H4 receptors decreases epithelial-to-mesenchymal transition progress by inhibiting transforming growth factor-β1 signalling pathway in non-small cell lung cancer.
Cai WK; Hu J; Li T; Meng JR; Ma X; Yin SJ; Zhao CH; He GH; Xu GL
Eur J Cancer; 2014 Apr; 50(6):1195-206. PubMed ID: 24447834
[TBL] [Abstract][Full Text] [Related]
25. Epithelial mesenchymal transition (EMT) and non-small cell lung cancer (NSCLC): a mutual association with airway disease.
Mahmood MQ; Ward C; Muller HK; Sohal SS; Walters EH
Med Oncol; 2017 Mar; 34(3):45. PubMed ID: 28197929
[TBL] [Abstract][Full Text] [Related]
26. ING5 inhibits lung cancer invasion and epithelial-mesenchymal transition by inhibiting the WNT/β-catenin pathway.
Liu XL; Meng J; Zhang XT; Liang XH; Zhang F; Zhao GR; Zhang T
Thorac Cancer; 2019 Apr; 10(4):848-855. PubMed ID: 30810286
[TBL] [Abstract][Full Text] [Related]
27. EMT is associated with, but does not drive resistance to ALK inhibitors among EML4-ALK non-small cell lung cancer.
Gower A; Hsu WH; Hsu ST; Wang Y; Giaccone G
Mol Oncol; 2016 Apr; 10(4):601-9. PubMed ID: 26639656
[TBL] [Abstract][Full Text] [Related]
28. ID1 mediates resistance to osimertinib in EGFR T790M-positive non-small cell lung cancer through epithelial-mesenchymal transition.
Liu K; Chen X; Wu L; Chen S; Fang N; Cai L; Jia J
BMC Pulm Med; 2021 May; 21(1):163. PubMed ID: 33992097
[TBL] [Abstract][Full Text] [Related]
29. Reversal of epithelial-mesenchymal transition and inhibition of tumor stemness of breast cancer cells through advanced combined chemotherapy.
Cui Y; Zhao M; Yang Y; Xu R; Tong L; Liang J; Zhang X; Sun Y; Fan Y
Acta Biomater; 2022 Oct; 152():380-392. PubMed ID: 36028199
[TBL] [Abstract][Full Text] [Related]
30. SOX9 drives the epithelial-mesenchymal transition in non-small-cell lung cancer through the Wnt/β-catenin pathway.
Huang JQ; Wei FK; Xu XL; Ye SX; Song JW; Ding PK; Zhu J; Li HF; Luo XP; Gong H; Su L; Yang L; Gong LY
J Transl Med; 2019 May; 17(1):143. PubMed ID: 31060551
[TBL] [Abstract][Full Text] [Related]
31. Simulation of multiple microenvironments shows a pivot role of RPTPs on the control of Epithelial-to-Mesenchymal Transition.
Pais RJ
Biosystems; 2020 Dec; 198():104268. PubMed ID: 33068671
[TBL] [Abstract][Full Text] [Related]
32. TGF-β1-induced epithelial-mesenchymal transition in lung cancer cells involves upregulation of miR-9 and downregulation of its target, E-cadherin.
Wang H; Wu Q; Zhang Y; Zhang HN; Wang YB; Wang W
Cell Mol Biol Lett; 2017; 22():22. PubMed ID: 29118814
[TBL] [Abstract][Full Text] [Related]
33. Comparison of EMT mediated tyrosine kinase inhibitor resistance in NSCLC.
Iderzorig T; Kellen J; Osude C; Singh S; Woodman JA; Garcia C; Puri N
Biochem Biophys Res Commun; 2018 Feb; 496(2):770-777. PubMed ID: 29337056
[TBL] [Abstract][Full Text] [Related]
34. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
Katayama R; Sakashita T; Yanagitani N; Ninomiya H; Horiike A; Friboulet L; Gainor JF; Motoi N; Dobashi A; Sakata S; Tambo Y; Kitazono S; Sato S; Koike S; John Iafrate A; Mino-Kenudson M; Ishikawa Y; Shaw AT; Engelman JA; Takeuchi K; Nishio M; Fujita N
EBioMedicine; 2016 Jan; 3():54-66. PubMed ID: 26870817
[TBL] [Abstract][Full Text] [Related]
35. MTA1 promotes epithelial to mesenchymal transition and metastasis in non-small-cell lung cancer.
Ma K; Fan Y; Dong X; Dong D; Guo Y; Wei X; Ning J; Geng Q; Wang C; Hu Y; Li M; Niu W; Li E; Wu Y
Oncotarget; 2017 Jun; 8(24):38825-38840. PubMed ID: 28418915
[TBL] [Abstract][Full Text] [Related]
36. LncRNA FEZF1-AS1 enhances epithelial-mesenchymal transition (EMT) through suppressing E-cadherin and regulating WNT pathway in non-small cell lung cancer (NSCLC).
He R; Zhang FH; Shen N
Biomed Pharmacother; 2017 Nov; 95():331-338. PubMed ID: 28858731
[TBL] [Abstract][Full Text] [Related]
37. The crosstalk between p38 and Akt signaling pathways orchestrates EMT by regulating SATB2 expression in NSCLC cells.
Kucuksayan H; Akca H
Tumour Biol; 2017 Sep; 39(9):1010428317706212. PubMed ID: 28937318
[TBL] [Abstract][Full Text] [Related]
38. FOXP3 promotes tumor growth and metastasis by activating Wnt/β-catenin signaling pathway and EMT in non-small cell lung cancer.
Yang S; Liu Y; Li MY; Ng CSH; Yang SL; Wang S; Zou C; Dong Y; Du J; Long X; Liu LZ; Wan IYP; Mok T; Underwood MJ; Chen GG
Mol Cancer; 2017 Jul; 16(1):124. PubMed ID: 28716029
[TBL] [Abstract][Full Text] [Related]
39. A pan-cancer analysis of FAT atypical cadherin 4 (FAT4) in human tumors.
Mao W; Zhou J; Hu J; Zhao K; Fu Z; Wang J; Mao K
Front Public Health; 2022; 10():969070. PubMed ID: 36051999
[TBL] [Abstract][Full Text] [Related]
40. Interaction of hnRNP K with MAP 1B-LC1 promotes TGF-β1-mediated epithelial to mesenchymal transition in lung cancer cells.
Li L; Yan S; Zhang H; Zhang M; Huang G; Chen M
BMC Cancer; 2019 Sep; 19(1):894. PubMed ID: 31492158
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
